CompanyGraph
What stands out
- Most companies in its industry are production businesses; this one is a flow business
At a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- ScaleLevered free cash flow is $28.28M, above the global median of $18.73M
- PositionCurrent ratio is 1.13×, lower than 95% of its Medical Devices peers (median 3.87×)
- Interpretations8 currently firing — 8
What this company is and how it runs — written from structure, not news.
What stands out
- Most companies in its industry are production businesses; this one is a flow business
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
346.98MUSDvs all stocks (USD)
Trailing P/E
24.75xvs Medical Devices peers
Revenue (TTM)
301.61MUSDvs all stocks (USD)
Profit Margin
4.81%vs Medical Devices peers
Beta
1.09xvs all stocks
52-Week Change
37.61%vs all stocks
Market Capitalization
346.98MUSDvs all stocks (USD)
Enterprise Value
342.22MUSDvs all stocks (USD)
Trailing P/E
24.75xvs Medical Devices peers
Forward P/E
22.27xvs Medical Devices peers
PEG Ratio
-1.98xvs Medical Devices peers
Price to Sales (TTM)
1.13xvs Medical Devices peers
Price to Book (MRQ)
2.36xvs Medical Devices peers
Enterprise to Revenue
1.14xvs Medical Devices peers
Enterprise to EBITDA
6.13xvs Medical Devices peers
Gross Margin
57.68%vs Medical Devices peers
Profit Margin
4.81%vs Medical Devices peers
Operating Margin
6.48%vs Medical Devices peers
Return on Assets (TTM)
8.21%vs Medical Devices peers
Return on Equity (TTM)
10.45%vs Medical Devices peers
Revenue (TTM)
301.61MUSDvs all stocks (USD)
Revenue per Share (TTM)
7.87USDUpdated Sep 28, 2026Quarterly Revenue Growth
23.90%vs Medical Devices peers
Gross Profit (TTM)
173.32MUSDvs all stocks (USD)
EBITDA (TTM)
55.50MUSDvs all stocks (USD)
Net Income (TTM)
14.50MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
-12.40%vs Medical Devices peers
Operating Cash Flow (TTM)
60.78MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
28.28MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 28, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Medical Devices peers
Minority Interest (Equity)
1.98MUSDFY2025 · Dec 31, 2025Revenue
270.28MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
114.82MUSDFY2025 · Dec 31, 2025Gross Profit
155.46MUSDFY2025 · Dec 31, 2025Operating Income
20.71MUSDvs all stocks (USD)
Pre-tax Income
21.77MUSDFY2025 · Dec 31, 2025Income Tax Expense
6.39MUSDFY2025 · Dec 31, 2025Net Income
15.38MUSDFY2025 · Dec 31, 2025EBIT
22.95MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
49.32MUSDFY2025 · Dec 31, 2025Research & Development
3.02MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
130.50MUSDFY2025 · Dec 31, 2025Other Operating Expenses
-252.00KUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
1.18MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
15.38MUSDFY2025 · Dec 31, 2025Minority Interests (P&L)
-442.00KUSDFY2025 · Dec 31, 2025Operating Cash Flow
54.40MUSDFY2025 · Dec 31, 2025Free Cash Flow
30.57MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
13.50MUSDFY2025 · Dec 31, 2025Income Tax Paid
7.39MUSDFY2025 · Dec 31, 2025Interest Paid
874.00KUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
15.38MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
28.61MUSDFY2025 · Dec 31, 2025Deferred Taxes (CF)
3.11MUSDFY2025 · Dec 31, 2025Stock-based Compensation
9.13MUSDFY2025 · Dec 31, 2025Other Non-cash Items
228.00KUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
1.16MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
479.00KUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-3.69MUSDFY2025 · Dec 31, 2025Capital Expenditures
-23.83MUSDFY2025 · Dec 31, 2025Net Acquisitions
-26.33MUSDFY2025 · Dec 31, 2025Sale of Investments
0.00USDFY2025 · Dec 31, 2025Net Investing Cash Flow
-50.17MUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
22.00MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-13.78MUSDFY2025 · Dec 31, 2025Common Stock Repurchase
-14.96MUSDFY2025 · Dec 31, 2025Other Financing Charges
-489.00KUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
-7.23MUSDFY2025 · Dec 31, 2025Shares Outstanding
38.09MSharesUpdated Sep 28, 2026Float Shares
30.64MSharesUpdated Sep 28, 2026Shares Short
1.32MSharesUpdated Sep 28, 2026Short Ratio
3.80daysvs all stocks
Short % of Shares Outstanding
4.03%vs all stocks
% Held by Insiders
13.93%vs all stocks
% Held by Institutions
71.19%vs all stocks
Total Cash (MRQ)
10.68MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
0.2800USDUpdated Sep 28, 2026Total Debt (MRQ)
11.60MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0795xvs Medical Devices peers
Current Ratio (MRQ)
1.13xvs Medical Devices peers
Book Value per Share (MRQ)
3.78USDUpdated Sep 28, 2026Total Assets
199.15MUSDvs all stocks (USD)
Total Current Assets
48.49MUSDFY2025 · Dec 31, 2025Total Liabilities
55.63MUSDFY2025 · Dec 31, 2025Total Non-current Assets
150.66MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
14.58MUSDFY2025 · Dec 31, 2025Total Current Liabilities
41.06MUSDFY2025 · Dec 31, 2025Cash
7.20MUSDFY2025 · Dec 31, 2025Cash Equivalents
6.30MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
13.50MUSDFY2025 · Dec 31, 2025Accounts Receivable
25.59MUSDFY2025 · Dec 31, 2025Inventory
5.05MUSDFY2025 · Dec 31, 2025Accounts Payable
12.33MUSDFY2025 · Dec 31, 2025Short-term Debt
2.29MUSDFY2025 · Dec 31, 2025Deferred Revenue
7.52MUSDFY2025 · Dec 31, 2025Other Current Liabilities
1.65MUSDFY2025 · Dec 31, 2025Long-term Debt
13.65MUSDFY2025 · Dec 31, 2025Common Stock (Book)
16.91MUSDFY2025 · Dec 31, 2025Retained Earnings
102.89MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
143.52MUSDvs all stocks (USD)
52-Week Low
6.05USDUpdated Sep 28, 202652-Week High
12.61USDUpdated Sep 28, 202652-Week Change
37.61%vs all stocks
Beta
1.09xvs all stocks
50-Day MA
9.72USDUpdated Sep 28, 2026200-Day MA
9.29USDUpdated Sep 28, 2026Avg 10-Day Volume
265.72KSharesUpdated Sep 28, 2026Avg 30-Day Volume
338.61KSharesUpdated Sep 28, 2026Diluted EPS (TTM)
0.3600USDUpdated Sep 28, 2026Other Income / Expense
2.24MUSDFY2025 · Dec 31, 20258 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
MRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Cash covers most of its debt, with earnings high against its liabilities.
Reads
How does this company use capital?
FCF Ratios Elevated
Its free cash flow is large next to assets and equity, and more of its operating cash reaches it than in its industry.
Reads
Industry-Benchmarked Return on Capital Elevated
It earns more on its assets and its equity than its industry, and gets more sales from those assets.
Reads
Multi-Year FCF With Growth And Margin
Three years of positive free cash flow and rising revenue, four of rising equity, and much of its sales turns into cash.
Reads
Revenue Growing With Receivables Growing
Revenue has risen three years, and what customers owe has risen with it.
Reads
Is this company growing?
Multi-Year Revenue, Profit, And Income Growth
Revenue has risen in each of three years, gross profit in each of four, and it has made a profit in all five.
Reads
How is this stock valued?
High Retained Earnings With Profitability And Equity
Profits kept in the business fund much of what it owns, after five straight profitable years.
Reads
Where is this company structurally exposed?
Receivables Heavy and Growing
Money owed by customers keeps growing, and is much of its current assets.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Current ratio is 1.13×, lower than 95% of its Medical Devices peers (median 3.87×)Significant
Current ratio: 1.13Industry median: 3.87Industry P5: 1.33Peers compared: 102
Structural Tensions
Most companies in its industry are production businesses; this one is a flow businessSignificant
Industry peers: 174Share on the common pattern %: 98.00
High gross margins eroded by operating costsNotable
Gross Margin: 0.58Profit Margin: 0.05
Financial Health
Altman Z-Score 6.25: safe zoneNotable
Altman Z-Score: 6.25
High earnings qualityNotable
Earnings Quality Score: 2.91
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Scale
Levered free cash flow is $28.28M, above the global median of $18.73MNotable
Levered free cash flow (USD): 28,275,124Global Median: 18,729,043.027
Companies that share the same coordination system — how they create, deliver, or capture value.
Dimed S.A. Distribuidora de Medicamentos
Tier 1FlowApproval-Gated PipelineInterfaceRule
AdaptHealth Corp.
Tier 1FlowApproval-Gated PipelineInterfaceProduction
Lumexa Imaging Holdings, Inc.
Tier 1FlowApproval-Gated PipelineInterfaceRule
Nanjing Pharmaceutical Co., Ltd.
Tier 1FlowApproval-Gated PipelineInterfaceRule
Iridium Corporation
Tier 1FlowApproval-Gated PipelineProduction
Hyundai Movex Co., Ltd.
Tier 1FlowApproval-Gated PipelineProductionRisk
Shanghai Ya Tong Co., Ltd.
Tier 3FlowThroughput-Bound ConversionProductionInterface
Diana Shipping Inc.
Tier 3FlowThroughput-Bound ConversionProductionRisk
PTG Energy Public Company Limited
Tier 3FlowUnit ReplicationInterfaceProduction
Mie Kotsu Group Holdings Inc.
Tier 3FlowThroughput-Bound ConversionProductionInterface
Companies that share active interpretations — structural patterns currently present in both stocks.
Catalyst Pharmaceuticals Inc.
7 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesHigh Retained Earnings With Profitability And EquityFCF Ratios ElevatedRevenue Growing With Receivables GrowingMulti-Year Revenue, Profit, And Income GrowthIndustry-Benchmarked Return on Capital ElevatedMulti-Year FCF With Growth And Margin
NVIDIA Corporation
7 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesHigh Retained Earnings With Profitability And EquityFCF Ratios ElevatedRevenue Growing With Receivables GrowingMulti-Year Revenue, Profit, And Income GrowthIndustry-Benchmarked Return on Capital ElevatedMulti-Year FCF With Growth And Margin
Comfort Systems USA, Inc.
7 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesFCF Ratios ElevatedReceivables Heavy and GrowingRevenue Growing With Receivables GrowingMulti-Year Revenue, Profit, And Income GrowthIndustry-Benchmarked Return on Capital ElevatedMulti-Year FCF With Growth And Margin